Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mai 2016 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio’s Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress

SOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...
05 mai 2016 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...
19 avr. 2016 17h15 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor

Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research (AACR) Annual Meeting Atara Bio and QIMR Berghofer Collaborating to Develop Next Generation...
06 avr. 2016 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio to Present at the 15th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and...
28 mars 2016 16h05 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences

SOUTH SAN FRANCISCO, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and...
23 mars 2016 09h15 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder

SOUTH SAN FRANCISCO, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and...
16 mars 2016 16h45 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...
03 mars 2016 16h05 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...
29 févr. 2016 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio to Present at the Cowen and Company 36th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...
08 févr. 2016 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...

Page précédente